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OBJECTIVE—Most pancreatic endocrine cells derive from
Ptf1a-expressing progenitor cells. In humans, nonsense muta-
tions in Ptf1a have recently been identiﬁed as a cause of
permanent neonatal diabetes associated with pancreatic agene-
sis. The death of Ptf1a-null mice soon after birth has not allowed
further insight into the pathogenesis of the disease; it is therefore
unclear how much pancreatic endocrine function is dependent
on Ptf1a in mammals. This study aims to investigate gene-dosage
effects of Ptf1a on pancreas development and function in mice.
RESEARCH DESIGN AND METHODS—Combining hypomor-
phic and null alleles of Ptf1a and Cre-mediated lineage tracing,
we followed the cell fate of reduced Ptf1a-expressing progeni-
tors and analyzed pancreas development and function in mice.
RESULTS—Reduced Ptf1a dosage resulted in pancreatic hyp-
oplasia and glucose intolerance with insufﬁcient insulin secretion
in a dosage-dependent manner. In hypomorphic mutant mice,
pancreatic bud size was small and substantial proportions of
pancreatic progenitors were misspeciﬁed to the common bile
duct and duodenal cells. Growth with branching morphogenesis
and subsequent exocrine cytodifferentiation was reduced and
delayed. Total -cell number was decreased, proportion of non-
islet cells was increased, and -cells were abnormally intermin-
gled with -cells. Interestingly, Pdx1 expression was decreased
in early pancreatic progenitors but elevated to normal level at the
mid-to-late stages of pancreatogenesis.
CONCLUSIONS—The dosage of Ptf1a is crucial for pancreas
speciﬁcation, growth, total -cell number, islet morphogenesis,
and endocrine function. Some neonatal diabetes may be caused
by mutation or single nucleotide polymorphisms in the Ptf1a
gene that reduce gene expression levels. Diabetes 57:2421–
2431, 2008
S
patiotemporally regulated expression of tran-
scription factors is important for cell fate speci-
ﬁcation and organogenesis. It is becoming
recognized that the absolute level of a speciﬁc
transcription factor is also an important component for
cell fate speciﬁcation and differentiation, e.g., myogenin
for skeletal muscle formation (1) and Sox2 for retinal
progenitor cell differentiation and for the patterning and
differentiation of anterior foregut endoderm (2,3). In pan-
creatogenesis, reduced dosage of Pdx1 by deleting pro-
moter elements of Pdx1 causes a block in ventral pancreas
speciﬁcation and impaired dorsal pancreas development,
resulting in glucose intolerance (4).
Ptf1a (PTF1-p48), a bHLH transcription factor, is indis-
pensable for the formation of the exocrine pancreas and
the correct spatial organization of the endocrine pancreas
in mice (5). Originally, Ptf1a was reported as a transcrip-
tional regulator for acinar cell–speciﬁc genes such as
elastase 1 and amylase (6,7). Using Cre-mediated lineage
tracing, we previously showed that all pancreatic exocrine
cells and most endocrine cells derive from Ptf1a-express-
ing progenitors. Furthermore, by combining gene knock-
out and lineage tracing, we showed that Ptf1a-inactivated
cells revert to an intestinal cell fate, demonstrating its
function as a switch between pancreatic and intestinal cell
fates (8). Supporting this notion, we and other groups
recently demonstrated that ectopic expression of Ptf1a in
the Pdx1-expressing undifferentiated endoderm results in
a pancreatic cell fate and induces the full-scale pancreatic
developmental program in mice and Xenopus (9–11). Very
recently, it was shown that Ptf1a is one marker of early
pancreatic multipotent progenitor cells located in the tips
of the developing pancreatic epithelial tree (12). Ptf1a is
not essential for pancreatic endocrine differentiation (5,8),
and Ptf1a is not expressed in mature pancreatic endocrine
cells (6). Nevertheless, in humans, nonsense mutations in
Ptf1a were recently identiﬁed as a cause of permanent
neonatal diabetes associated with pancreatic agenesis
(13). The death of Ptf1a-null mice soon after birth has not
allowed further insight into the pathogenesis of the dis-
ease; therefore, it is still unclear how much pancreatic
endocrine function is dependent on Ptf1a in mammals.
Moreover, there is no information about gene-dosage
effect of Ptf1a on pancreas development and function in
mice.
In the present study, we used a combination of hypo-
morphic and null alleles of Ptf1a and a Cre-mediated
lineage-tracing approach to show that reduced dosage of
Ptf1a results in pancreatic hypoplasia and glucose intol-
erance in mice. We provide evidence that there is a
threshold of Ptf1a dosage by which pancreatic progenitor
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they otherwise are misspeciﬁed to other organs (common
bile duct [CBD]/duodenum) and cannot adequately expand
in number. We also show defects in endocrine pancreas
development (total -cell number, ratios of endocrine cell
types, and islet architecture) in Ptf1a hypomorphic mutant
mice.
RESEARCH DESIGN AND METHODS
Ptf1a
cre/ (8), Ptf1a
cbll/ (14), and ROSA26r mice (15) were crossed in the
C57BL/6 background and interbred to produce Ptf1a
cre/;ROSA26r, Ptf1a
cre/cbll;
ROSA26r, Ptf1a
cre/cre;ROSA26r, and Ptf1a
cbll/cbll mice. All animal experiments
were performed in accordance with the guidelines for animal experiments of
Kyoto University.
RNA isolation and quantitative real-time RT PCR. Pancreatic rudiments
were dissected and submerged in RNA Later (Qiagen, Tokyo, Japan). Total
RNA was extracted using an RNeasy Mini Kit (Qiagen). First-strand cDNA
synthesis was performed using Superscript III ﬁrst-strand synthesis systems
(Invitrogen). Quantiﬁcation of Ptf1a and Pdx1 gene expression was per-
formed by quantitative real-time RT-PCR using the 7300 Real-Time PCR
System (Applied Biosystems). The Ptf1a and Pdx1 probes were TaqMan Gene
Expression Assay nos. Mm00479622_m1 and Mm00435565_m1 (Applied Bio-
systems), respectively. Data were normalized in relation to the expression of
GAPDH.
Histology. Tissue processing, X-gal staining, and permeabilization were
performed as described previously (8,9). The following primary antibodies
were used: guinea pig anti-insulin (DAKO), rabbit anti-amylase (Sigma-
Aldrich), rabbit anti-glucagon (DAKO), rabbit anti-somatostatin (DAKO), rabit
anti-pancreatic polypeptide (DAKO), goat anti-Pdx1, goat anti-glut2 (Santa
Cruz Biotechnology), mouse anti-cytokeratin (DAKO), and rabbit anti-phos-
phorylated histone H3 (Upstate). The immunoﬂuorescent secondary antibod-
ies were Cy3-conjugated antibody to guinea pig IgG (Cy3-conjugated antibody
to rabbit IgG; Chemicon), Alexa Fluor 488-conjugated antibody to rabbit
IgG (Molecular Probes), Alexa Fluor 488-conjugated antibody to mouse IgG
(Molecular Probes), and Alexa Fluor 488-conjugated antibody to goat IgG
(Molecular Probes). Transferase-mediated dUTP nick-end labeling (TUNEL)
assays were performed using the DeadEnd Fluorometric TUNEL system
(Promega). Images were visualized using a Zeiss Axioskop 2 microscope.
Quantiﬁcation of total -cell number was performed by serially sectioning the
entire pancreas followed by staining and counting every 10th section for
embryonic day (e)14.5 embryos or every 20th section for e18.5 embryos (n 
3) in each genotype. The ratios of endocrine cell types were calculated from
eight randomly chosen sections costained with hormones per animal (n  3)
in each genotype. Homogenized stool samples were centrifuged, and the
supernatant was stained with Oil Red O solution (Sigma).
Glucose tolerance test and enzyme-linked immunosorbent assay. Glu-
cose tolerance tests were performed by injecting D-glucose (2 mg/kg i.p.) after
overnight fasting. For measurements of serum insulin, D-glucose (2 mg/g body
wt i.p.) was injected and 15 min later blood was collected into tubes
containing aprotinin (100 KIE/ml blood; Wako) and centrifuged to obtain
serum. Plasma insulin levels were measured using the Mouse Insulin ELISA kit
(u-type) (Shibayagi, Gunma, Japan).
Statistical analyses. Data are presented as mean  SE. Data were subjected
to unpaired t test or one-way nonrepeated measurements ANOVA with
Bonferonni tests. P  0.05 was considered signiﬁcant.
RESULTS
Reduction of Ptf1a dosage resulted in small body size
and pancreatic hypoplasia. A hypomorphic allele of
Ptf1a (Ptf1a
cbll) has a 313-kb genomic deletion located 60
kb downstream of the Ptf1a locus, but the Ptf1a locus
itself is intact (14). The Ptf1a
cre allele is null through the
replacement of the Ptf1a protein-coding region with that
of a nuclearly targeted Cre recombinase (8). We used
quantitative real-time RT-PCR to evaluate the expression
level of Ptf1a in pancreata from Ptf1a
cre/, homozygous
Ptf1a
cbll/cbll, and compound trans-heterozygotes of Ptf1a
cre
and Ptf1a
cbll (Ptf1a
cre/cbll) compared with that in wild-type
mice at two stages: e12.5, when Ptf1a is expressed in the
multipotent progenitor phase of pancreas development
(12), and postnatal day 1 (P1), when Ptf1a is expressed in
exocrine cells in pancreas. Ptf1a RNA levels in pancreatic
rudiments from Ptf1a
cre/, Ptf1a
cbll/cbll, and Ptf1a
cre/cbll
mice were substantially reduced to 55  8, 32  10, and
14  4%, respectively, compared with wild-type mice at
e12.5, and they were reduced to 60  7, 48  4, and 30 
6%, respectively, at P1 (Fig. 1A).
Hypomorphic Ptf1a
cre/cbll and Ptf1a
cbll/cbll mice were
born at the expected Mendelian ratio. Ptf1a
cre/cbll mice
appeared small and dehydrated at birth. Some Ptf1a
cre/cbll
mice survived to P30 (the longest survival up to P45), but
the rest died before P14. On the other hand, Ptf1a
cre/,
Ptf1a
cbll/cbll, and wild-type mice were almost indistinguish-
able from each other at birth and were viable. As shown in
Fig. 1B–D, postnatal growth retardation and small body
size persisted into the weaning stage in Ptf1a
cre/cbll and
Ptf1a
cbll/cbll mice. We crossed Ptf1a
cre/ and Ptf1a
cre/cbll
with Gt(ROSA)26Sor
tm1Sor (R26r) mice, which carry a
ﬂoxed lacZ gene driven by cell type–independent ROSA
promoter (15), enabling us to trace the fate of all Ptf1a-
expressing cells and their progeny (8). Macroscopically,
the pancreas of hypomorphic Ptf1a
cre/cbll;R26r mice was
dramatically smaller than that of Ptf1a
cre/;R26r mice at
birth (data not shown), at P7, and at P30, and Ptf1a
cbll/cbll
mice exhibited moderate pancreatic hypoplasia (Fig. 1E–
J).
Cell fate conversion of pancreatic precursors into
the CBD and duodenal cells in Ptf1a
cre/cbll;R26r mice.
Pancreas development can be divided into four phases in
mice: The ﬁrst phase is the speciﬁcation and formation of
dorsal and ventral pancreatic buds from foregut endoderm
(speciﬁcation). During the second phase, extensive prolif-
eration and branching of the pancreatic epithelium occur
(branching morphogenesis). The third phase involves dif-
ferentiation of large numbers of endocrine, exocrine, and
duct cell lineages (cytodifferentiation). The fourth phase
consists of maturation of the islet architecture and func-
tion in the postnatal period (islet morphogenesis). Devel-
opmentally, as shown in Fig. 2A–H, pancreas was small
from the beginning of pancreatic bud formation at e10.5 in
Ptf1a
cre/cbll;R26r mice compared with Ptf1a
cre/;R26r lit-
termates, and this size difference became more apparent
as development proceeded.
In our previous study, lineage-labeled -galactosidase
(-gal)-positive cells were observed in the duodenum in
both the dorsal and ventral regions in Ptf1a-null (Ptf1a
cre/cre;
R26r) mice (8). A subset of -gal–positive cells were found
to protrude from the gut tube in the ventral region at e12.5,
but the cell fate of these cells was not identiﬁed (8). In
hypomorphic Ptf1a
cre/cbll;R26r mice, at the dorsal side,
ectopic Ptf1a lineage-labeled areas were observed in the
duodenum at P7, similar to Ptf1a
cre/cre;R26r mice at e17.5
(Fig. 1G and Fig. 2J). Notably, at the ventral side, not only
the duodenum but also the CBD contained ectopic Ptf1a
lineage-labeled cells in Ptf1a
cre/cbll;R26r at e17.5 and P7
(Fig. 2H and L) and in Ptf1a
cre/cre;R26r mice at e17.5 (Fig.
2K). Histologically, substantial proportions of Ptf1a lin-
eage-labeled cells were misspeciﬁed and adopted a Cdx2
(16)-positive duodenal epithelial cell fate or cytokeratin-
positive CBD epithelial cell fates including cells of the
peribiliary glands (17) in Ptf1a
cre/cbll;R26r mice (Fig. 2M–
Q). These results indicate that a threshold level of Ptf1a
expression is required for the acquisition of a pancreatic
cell fate in the primitive foregut endoderm and that
reduction of Ptf1a dosage results in misspeciﬁcation of
pancreatic progenitors into the CBD and duodenum. Thus,
together with reduced pancreatic bud size at early devel-
opmental stages, reduction of Ptf1a dosage results in a
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2422 DIABETES, VOL. 57, SEPTEMBER 2008FIG. 1. Reduction of Ptf1a dosage results in small body size and pancreatic hypoplasia. A: Quantiﬁcation of Ptf1a mRNA in pancreata by real-time
RT-PCR. The relative expression levels of Ptf1a mRNA in pancreata from Ptf1a hypomorphic mice are shown compared with wild-type mice at
e12.5 and P1. Data are expressed as means  SE (n  4). *P < 0.05, **P < 0.01. B and C: Gross appearance of Ptf1a
cre/cbll mice compared with
Ptf1a
cre/ littermates (B) and Ptf1a
cbll/cbll mice compared with wild-type littermate (C) at P23. D: Body weights of Ptf1a
cre/, Ptf1a
cbll/cbll, and
Ptf1a
cre/cbll mice during postnatal periods. Data are expressed as means  SE. *P < 0.05 compared with Ptf1a
cre/ mice. E–G: Macroscopic views
of pancreata of Ptf1a
cre/;R26r (E), Ptf1a
cbll/cbll (F), and Ptf1a
cre/cbll;R26r mice (G) at P7 stained with X-gal. Broken lines delineate pancreata in
F, H, and I. At P30, pancreatic hypoplasia is observed in Ptf1a
cbll/cbll (I) and Ptf1a
cre/cbll;R26r mice (J) compared with Ptf1a
cre/ mice (H). (Please
see http://dx.doi.org/10.2337/db07-1558 for a high-quality digital representation of this ﬁgure.)
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DIABETES, VOL. 57, SEPTEMBER 2008 2423FIG. 2. Cell fate conversion of pancreatic precursors into the CBD and duodenal cells in hypomorphic Ptf1a
cre/cbll mice. A–L: Macroscopic views
of pancreatic regions stained with X-gal. Hypomorphic pancreas is observed from the beginning of pancreatic bud formation at e10.5 (B) and
becomes more apparent as development proceeds to e14.5 (D) and e17.5 (F and H)i nPtf1a
cre/cbll;R26r mice. Broken lines in (I) delineate
moderate hypoplastic pancreas in Ptf1a
cbll/cbll mice at e17.5. Note that substantial proportions of the Ptf1a lineage-labeled cells are ectopically
observed in the CBD (red arrows in H) and the duodenum (Du) (outlined boxes in H and L)i nPtf1a
cre/cbll;R26r mice at e17.5 (H) and P7 (L).
Endogenous -gal activity is observed in the duodenum as background. The cell fate conversion to the CBD is observed in Ptf1a
cre/cbll;R26r mice
as early as e14.5 (red arrows in D). Ectopic Ptf1a lineage-labeled areas are also observed in the CBD and duodenum in Ptf1a
cre/cre;R26r mice at
e17.5 (J and K). M–Q: Histological analyses of Ptf1a
cre/cbll;R26r mice at P7. Substantial proportions of Ptf1a lineage-labeled cells are misspeciﬁed
and located to the CBD epithelium (arrows in M and N [M and N are the same sections]), including the peribiliary glands (arrows in O) and
duodenal epithelial cells (P) stained with hematoxylin and eosin, which are positive for cytokeratin (red; arrow in N) and the intestinal marker
Cdx2 (brown; Q), respectively, in Ptf1a
cre/cbll;R26r mice. (Please see http://dx.doi.org/10.2337/db07-1558 for a high-quality digital representation
of this ﬁgure.)
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atic cell fate.
Cell proliferation of the early pancreatic precursors
is decreased in hypomorphic Ptf1a
cre/cbll mice. Next,
we investigated whether reduction of Ptf1a dosage affects
the growth of pancreatic precursor cells. Quantiﬁcation
revealed that signiﬁcantly more pancreatic precursor cells
are proliferating in Ptf1a
cre/ mice (12.0  2.1% of the total
Ptf1a lineage-labeled pancreatic epithelial cells) than in
Ptf1a
cre/cbll mice (5.9  1.9%) (n  4, ﬁve to seven sections
analyzed per embryo) at e10.5, as detected by the mitosis
maker phosphorylated histone H3 (Fig. 3D). At e12.5,
although the difference was not signiﬁcant (P  0.071),
more pancreatic precursor cells were proliferating in
Ptf1a
cre/ mice (6.3  1.2%) than in Ptf1a
cre/cbll mice (3.8 
1.2%) and Ptf1a
cre/cre mice (2.3  0.6%) (Fig. 3A–C and E).
On the other hand, TUNEL staining revealed that apopto-
tic cells are only rarely observed in both Ptf1a
cre/ and
hypomorphic mutant mice at e10.5 and e12.5 (data not
shown), suggesting that apoptosis does not contribute to
the hypomorphic pancreas of the mutants.
Delayed branching morphogenesis and reduced pan-
creatic exocrine differentiation with exocrine dys-
function in Ptf1a hypomorphic mice. As reported
previously, Ptf1a-null mice completely lack exocrine cy-
todifferentiation (5,8). In Ptf1a
cre/;R26r mice, extensive
branching morphogenesis of the pancreatic epithelial tree
was observed as early as e12.5, and amylase-positive cells
were detected at e14.5 (Fig. 4A.C). In Ptf1a
cre/cbll;R26r
mice, almost no branching morphogenesis of the pancre-
atic epithelial tree was seen, even at e14.5 (Fig. 4B and E).
Exocrine cytodifferentiation was also markedly delayed
and reduced (Fig. 4H, K, N, and Q–T). Amylase-positive
cells began to appear at P1 in small areas in Ptf1a
cre/cbll
mice, but they were morphologically immature in that the
nucleus-to-cytoplasm ratio in Ptf1a
cre/cbll mice at P1 was as
large as that in Ptf1a
cre/ mice at e14.5 (Fig. 4C and K). At
P7, pancreatic acinar structures were observed in re-
stricted ventral regions, but the majority of the cells
resembled immature duct-like epithelial structures that
phenotypically corresponded to those at e14.5 in
Ptf1a
cre/ mice (Fig. 4N and Q). In the adult stage,
amylase-positive acinar structures were detected in the
ventral pancreas and proximal dorsal pancreas, but the
majority of dorsal pancreas was composed of immature
duct-like epithelial cells that rarely expressed amylase
(Fig. 4R–T). Persistent Pdx1 expression was observed in
the immature duct-like epithelial cells at P1, P7, and P30,
while normal duct cells do not express Pdx1 at these
stages (Fig. 8E–G and I and data not shown). Thus, the
reduced dosage of Ptf1a falls below the threshold required
to elicit the proper pancreatic exocrine differentiation
program, and many pancreatic duct-like epithelial cells
appear to remain in an undifferentiated state until the adult
stage. These results also indicate regional (ventral vs.
dorsal and distal vs. proximal) differences in the exocrine
differentiation program of the dorsal pancreas related to
the Ptf1a dosage. Ptf1a
cbll/cbll mice showed intermediate
delay in branching morphogenesis and exocrine cyto-
differentiation during embryogenesis, but exocrine cyto-
differentiation was fully restored by adulthood (Fig. 4D, G,
J, M, and P). Actually, the body weights of Ptf1a
cbll/cbll mice
were almost similar to those of wild-type mice by 3 months
of age. As expected from the histological ﬁndings, Ptf1a
cre/cbll
mice showed exocrine pancreas dysfunction at P22, demon-
strated by the abundant Oil red O–stained lipid droplets in
stool smears (Fig. 4U). A small amount of lipid droplets was
also observed in stool smears from Ptf1a
cbll/cbll mice, but it
was very rare. Thus, we hypothesize that exocrine pan-
creas dysfunction is, at least in part, one of the causes of
growth retardation as well as impaired metabolic ho-
meostasis in Ptf1a
cre/cbll mice (see below).
FIG. 3. Decreased proliferation of early pancreatic precursors in Ptf1a hypomorphic mutant mice. A–C: Sections of pancreata stained with X-gal
and phosphorylated histone H3 (pHH3), a mitosis maker, at e12.5 (A–C). D and E: The ratios of pHH3-positive cells/Ptf1a lineage-labeled
pancreatic epithelial cells at e10.5 (D) and e12.5 (E). Data are expressed as means  SE (n  4). *P < 0.05 compared with Ptf1a
cre/ mice. (Please
see http://dx.doi.org/10.2337/db07-1558 for a high-quality digital representation of this ﬁgure.)
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DIABETES, VOL. 57, SEPTEMBER 2008 2425FIG. 4. Exocrine cytodifferentiation is reduced during development with delayed branching morphogenesis in hypomorphic mutant mice. A–T: Sections
of pancreata stained with X-gal (blue) and amylase (Amy, green). (Left panels in D, G, J, M, P, and R: hematoxylin and eosin [HE] staining.) Extensive
branching morphogenesis of the pancreatic epithelial tree is observed at both e12.5 and e14.5 in Ptf1a
cre/;R26r mice (A and C), whereas almost no
branching morphogenesis is observed in Ptf1a
cre/cbll;R26r mice at those stages (B and E). At e17.5, branching of the pancreatic epithelium could be
observed in Ptf1a
cre/cbll;R26r mice (H). At e14.5, amylase-positive cells are observed in Ptf1a
cre/ mice (C), whereas they are not seen at all in
Ptf1a
cre/cbll (E) and Ptf1a
cbll/cbll mice (D). Amylase-positive cells are ﬁrst apparent at P1 in Ptf1a
cre/cbll mice (K), but they are premature in that the
nucleus-to-cytoplasm ratio in pancreatic exocrine cells of Ptf1a
cre/cbll mice at P1 is as large as that of Ptf1a
cre/ mice at e14.5 (outlined boxes in K and
C). In some areas, normal pancreatic acinar structures are observed at P7 in Ptf1a
cre/cbll mice (Q), but the nucleus-to-cytoplasm ratio of the acinar cells
in Ptf1a
cre/cbll mice at P7 is as large as that of Ptf1a
cre/ mice at e17.5 (outlined boxes in Qand F). At P30, in the ventral pancreas (v.p.) and the proximal
dorsal pancreas (d.p.) in Ptf1a
cre/cbll mice, amylase-positive acinar structures are observed (arrows and outlined box in R and S), whereas, in their
dorsal pancreas, the duct-like structures still exist (arrowheads and dashed-line box in R) and rarely express amylase (T). In Ptf1a
cbll/cbll mice,
immature duct-like epithelial cells (arrowheads and dashed-lined boxes in J and M) are observed at P1 and P7, but acinar tissues are fully developed
at P30 (P). U: Stool smears of Ptf1a
cre/, Ptf1a
cbll/cbll, and Ptf1a
cre/cbll mice stained with Oil Red O. Large numbers of undigested lipid droplets are
observed in stool smears of Ptf1a
cre/cbll mice, indicative of maldigestion. Very rarely, a small amount of lipid droplets is also observed in stool smears
of Ptf1a
cbll/cbll mice. (Please see http://dx.doi.org/10.2337/db07-1558 for a high-quality digital representation of this ﬁgure.)
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secretion and glucose intolerance in Ptf1a hypo-
morphic mutants. During embryogenesis, the timing of
pancreatic endocrine cytodifferentiation was indistin-
guishable between Ptf1a
cre/, Ptf1a
cbll/cbll, and Ptf1a
cre/cbll
mice (Fig. 5A–L). However, analyses of endocrine cell
types at e18.5 revealed that the ratio of -t o-cells is
signiﬁcantly higher in Ptf1a
cre/cbll and Ptf1a
cbll/cbll mice and
the ratio of -t o-cells is signiﬁcantly higher in Ptf1a
cre/cbll
mice compared with Ptf1a
cre/ mice (n  3) (Fig. 5M).
Moreover, total number of -cells was signiﬁcantly lower
in Ptf1a
cre/cbll and Ptf1a
cbll/cbll mice compared with
Ptf1a
cre/ mice at both e14.5 and e18.5 in a Ptf1a dosage–
dependent manner (n  3) (Fig. 5N and O). At postnatal
stages (at P1 and at P30), islet architecture was disorga-
nized in both Ptf1a
cre/cbll and Ptf1a
cbll/cbll mice (Fig. 5D, H,
L, and P-R). The proportion of glucagon-producing cells
was increased, and many of them were abnormally inter-
mingled with islet -cells (Fig. 5P–R). Pancreatic polypep-
tide– and somatostatin-expressing cells were normally
localized in the periphery of islet but increased in
number in both Ptf1a
cbll/cbll and Ptf1a
cre/cbll mice (Fig.
5P–R). Nuclear Pdx1 and cell-membranous Glut2 ex-
pressions in individual -cells were similar to those in
wild-type mice at P30 (Fig. 5S–X), suggesting their
maturation.
To assess pancreas endocrine function, mice (23- to
30-day-old: wild-type, n  4; Ptf1a
cre/, n  16; Ptf1a
cbll/cbll,
FIG. 5. Endocrine pancreas development in Ptf1a hypomorphic mutant mice. A–L: Sections of pancreata costained for insulin (red) and glucagon
(green). Normal islet structures are observed in Ptf1a
cre/ mice at P1 (D), whereas they are not observed in Ptf1a
cbll/cbll (H) and Ptf1a
cre/cbll mice
(L). M: Ratios of endocrine cell types at e18.5 in Ptf1a
cre/ (red bars), Ptf1a
cbll/cbll (green bars), and Ptf1a
cre/cbll mice (purple bars). N and O:
Relative total -cell number at e14.5 (N) and e18.5 (O) in each genotype. P–R: Representative sections of pancreatic islets colabeled for insulin
(Ins, red) and glucagon (Glu, green), somatostatin (Som, green), or pancreatic polypeptide (PP, green) at P30. Note that pancreatic -, -, and
-cells are increased in number and -cells are intermingled with -cells in Ptf1a
cbll/cbll and Ptf1a
cre/cbll mice. S–X: Colabeling for Pdx1 (red) and
insulin (green) and staining for Glut2 (green) in islets. Pancreatic -cells express Pdx1 and Glut2 in all genotypes at P30, suggesting their
maturation. Data are expressed as means  SE (n  3). *P < 0.05 compared with Ptf1a
cre/ mice. (Please see http://dx.doi.org/10.2337/db07-1558
for a high-quality digital representation of this ﬁgure.)
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cre/cbll, n  6) were subjected to intra-
peritoneal glucose tolerance tests. Strikingly, Ptf1a
cre/cbll
mice showed dramatically elevated blood glucose levels 30
min after injection and remained hyperglycemic during the
entire testing period compared with wild-type and
Ptf1a
cre/ mice (Fig. 6A). Ptf1a
cbll/cbll mice exhibited mild
glucose intolerance (Fig. 6A). Serum insulin levels at 15
min after intraperitoneal glucose injection were inappro-
FIG. 7. Pdx1 expression levels are reduced in early pancreatic precursors in Ptf1a hypomorphic mutant mice. A–E: Sections of pancreata stained
with X-gal (blue) and Pdx1 (red). F and G: Sections of pancreata stained for hematoxylin and eosin (upper panels) and Pdx1 protein (lower
panels). Signal intensity is similar in the distal stomach epithelium, so that the Pdx1 expression level in pancreatic precursors can be judged
compared with it. Note that Pdx1 expression is reduced in pancreatic precursors at e10.5, e11.5, and e12.5 in Ptf1a
cre/cbll mice compared with
Ptf1a
cre/ and wild-type mice. G: Dashed line shows pancreatic epithelium. In Ptf1a null mice, Pdx1 expression is also reduced at e12.5 (E). H:
Quantiﬁcation of Pdx1 mRNA in pancreatic rudiments by real-time RT-PCR. The relative expression levels of Pdx1 in pancreatic rudiments from
Ptf1a hypomorphic mice are shown compared with wild-type mice at e12.5. Data are represented as means  SE (n  4). *P < 0.05 compared with
wild-type mice. Du, duodenum; St, distal stomach; P, pancreas. (Please see http://dx.doi.org/10.2337/db07-1558 for a high-quality digital
representation of this ﬁgure.)
FIG. 6. Impaired glucose tolerance with insufﬁcient insulin secretion in Ptf1a hypomorphic mutant mice. A: Blood glucose levels during
intraperitoneal glucose tolerance test (data from 21- to 30-day-old wild-type, n  4; Ptf1a
cre/, n  16; Ptf1a
cbll/cbll, n  33; and Ptf1a
cre/cbll mice,
n  6). Note that glucose intolerance is observed in a Ptf1a dosage–dependent manner. B: Serum insulin levels 15 min after intraperitoneal
glucose injection measured by enzyme-linked immunosorbent assay (data from 23- to 30-day-old wild-type, n  4; Ptf1a
cbll/cbll, n  9; and
Ptf1a
cre/cbll mice, n  5). Serum insulin levels are inappropriately lower in hypomorphic mutants compared with wild-type mice. Data are
expressed as means  SE. *P < 0.05 compared with wild-type mice.
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cre/cbll (39  0.6 pg/ml, n  5) and
Ptf1a
cbll/cbll mice (142  46 pg/ml, n  9) compared with
wild-type mice (453  107 pg/ml, n  5) (Fig. 6B).
Pdx1 expression is decreased in early pancreatic
precursors in Ptf1a
cre/cbll mice. Pdx1 is essential for
pancreas organogenesis and mature pancreatic -cell
function in mice and humans (18–20). A recent study has
shown that Ptf1a activates Pdx1 expression in vitro and
that endogenous Ptf1a binds the regulatory sequences of
Pdx1 in vivo (21,22). Consistent with these ﬁndings, Pdx1
expression was substantially reduced in pancreatic pre-
cursor cells in Ptf1a
cre/cbll mice at e10.5, e11.5, and e12.5
and in Ptf1a
cre/cre mice at e12.5 compared with Ptf1a
cre/
or wild-type mice (Fig. 7A–G, cf. signal intensity in the
distal stomach vs. dorsal pancreas). Pdx1 RNA levels in
pancreatic rudiments from Ptf1a
cbll/cbll and Ptf1a
cre/cbll
mice at e12.5 were signiﬁcantly decreased to 63  2 and
17  5%, respectively, compared with wild-type mice (Fig.
7H). Interestingly, Pdx1 expression and Pdx1 RNA levels
in Ptf1a hypomorphic and null mutants were elevated and
reached the same level as those in Ptf1a
cre/ and wild-type
mice at e14.5 and 17.5 (Fig. 8A–D, H, J, and K and data not
shown). Considering that Ptf1a dosage is still low at P1 in
each mutant, other positive regulators of Pdx1 would be
FIG. 8. Pdx1 expression persists in the postnatal pancreatic duck-like epithelial cells in Ptf1a hypomorphic mutant mice. Sections of pancreata
stained for X-gal (blue) and Pdx1 (red) (A–G and K) and stained for Pdx1 (H and I). The expression level of Pdx1 protein is similar among all
genotypes at e14.5 and e17.5. At P1 and P30, strong Pdx1 expression is observed in pancreatic -cells in Ptf1a
cre/ mice (arrowhead in E), and
its lower expression is maintained in pancreatic exocrine cells, whereas Pdx1 expression is not observed in duct cells (arrows in E). Note that
a moderate level of Pdx1 expression persists in the pancreatic duck-like epithelial cells in Ptf1a
cre/cbll mice at P1 (arrows in F) and P30 (G) and
in Ptf1a
cbll/cbll mice at P7 (arrows in I). The arrowhead in F shows strong Pdx1 expression in -cells in Ptf1a
cre/cbll mice. J: Quantiﬁcation of Pdx1
mRNA in pancreatic rudiments by real-time RT-PCR. The relative expression levels of Pdx1 in pancreatic rudiments of Ptf1a
cre/cbll mice are shown
compared with those of wild-type mice at e14.5. Data are expressed as means  SE (n  4). Du, duodenum; St, distal stomach; P, pancreas. (Please
see http://dx.doi.org/10.2337/db07-1558 for a high-quality digital representation of this ﬁgure.)
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of pancreatogenesis.
DISCUSSION
In the present study, combining hypomorphic and null
alleles of Ptf1a with Cre-loxP–based lineage tracing, we
have revealed dosage-dependent, crucial roles of Ptf1a in
pancreatic development and function, including 1) deter-
mination of pancreas size throughout embryogenesis until
the weaning stage, 2) cell fate determination of the pan-
creas versus CBD or duodenum in the developing foregut
endoderm, 3) growth with branching morphogenesis of
the epithelial tree and exocrine cytodifferentiation, 4) total
-cell number and balance of endocrine cell types, and 5)
islet morphogenesis and endocrine function in the postna-
tal period. These ﬁndings are implicated in possible patho-
genesis of pancreatic hypoplasia and neonatal diabetes in
humans.
The crucial role of Ptf1a dosage as a determinant of
pancreatic size. We have observed dosage-dependent
pancreatic hypoplasia in Ptf1a hypomorphic mutant mice.
Accounting for hypoplastic pancreas, we have revealed
that reduction of Ptf1a dosage results in a decrease of the
ﬁnal cell population that adopts a pancreatic cell fate.
Furthermore, we have shown that subsequent growth of
early pancreatic precursors is also reduced in Ptf1a hypo-
morphic mutants. Recently, it was reported that Pdx1

Ptf1a
 cMyc
high Cpa1
 multipotent progenitor cells are
located in the tip of the branching pancreatic epithelial
tree, while the trunk region of branches is composed of
endocrine and duct cell precursors (12). In Ptf1a hypo-
morphic mutants, it is conceivable that reduced branching
morphogenesis might result in the decrease in the number
of “multipotent tip cells.” In addition, consistent with the
recent studies (21,22), we have demonstrated that Ptf1a
dosage is crucial for the activation of Pdx1 in early
pancreatic progenitors in vivo. Considering that Pdx1
inactivation results in early growth arrest (19) and that
Pdx1 positively regulates Ptf1a in the early pancreatic
buds (4), it is concluded that Pdx1 and Ptf1a mutually
activate each other in early pancreatic precursors, estab-
lishing the pancreatic domains in the primitive endoderm
and promoting subsequent growth of pancreatic precur-
sors. It is noteworthy that Ptf1a dosage is one of the
“intrinsic” determinants of pancreatic size, which is rele-
vant to a recent study suggesting that the pancreas size is
determined by an intrinsic factor that is not amendable to
growth compensation (23). It remains possible that sub-
stantial pancreatoneogenesis is still occurring at P1, al-
though there is currently no evidence for multipotent
progenitor cells that express Ptf1a at P1 and afterward.
The critical role of Ptf1a dosage in cell fate speciﬁ-
cation. It is interesting that the cells expressing reduced
Ptf1a adopted different cell fates, including the CBD,
duodenum, and pancreas in Ptf1a
cre/cbll mice. Considering
that the expression level of Ptf1a per cell appears to not be
same in pancreatic buds at the early developmental stage
(12,24), it is likely that the cells that express Ptf1a above
a certain threshold level are speciﬁed to pancreas and
those cells expressing Ptf1a below this level are speciﬁed
to the CBD or duodenum. It is possible that the cells most
likely to be misspeciﬁed are those at the duodenal junc-
tion, since they could potentially still be receiving some
kind of gut fate-inducing signals that are stronger than in
the more distal cells. On the other hand, it is still an open
question as to how pancreatic endocrine versus exocrine
cell fate speciﬁcation is determined. In the recent study,
one striking observation is that Cpa1 becomes downregu-
lated in the cleft region when the branching tips divide and
Cpa1-expressing cells become incorporated into the trunk
region (12). In this study, we have found that pancreatic
exocrine cytodifferentiation is markedly delayed and re-
duced in Ptf1a hypomorphic mutants, whereas endocrine
cytodifferentiation is less affected. Together with the re-
port from Zhou et al. (12), our ﬁndings lead to an intriguing
hypothesis that Ptf1a dosage might be a determinant of
cell fate speciﬁcation of pancreatic exocrine versus endo-
crine lineage: The pancreatic progenitor cells that express
Ptf1a at a higher level are speciﬁed to exocrine lineage,
whereas those that express Ptf1a at lower level are
speciﬁed to endocrine lineage. It will be of considerable
interest to test this hypothesis by chimeric mouse exper-
iments using Ptf1a hypomorphic alleles.
The role of Ptf1a dosage in endocrine pancreas de-
velopment and glucose homoeostasis. The present
study shows that Ptf1a dosage affects total -cell number
and the balance of endocrine cell types as well as their
relative spatial relationships in late-stage endocrine cell
formation, although Ptf1a is not essential for endocrine
cytodifferentiation. It has been suggested that the sur-
rounding environment might be important for proper islet
formation (5). In Ptf1a hypomorphic mutants, appropriate
acinar tissues are not formed during embryognenesis and
the neonatal period; therefore, it is possible that lack of
production of the appropriate acinar tissue affects islet
formation. Alternatively, it is possible that downregulation
of Pdx1 in early pancreatic multipotent progenitors affects
a proportion of endocrine cell types in the mutants.
Reducing Pdx1 expression by deleting promoter elements
of Pdx1 gene results in disrupted proportion of each islet
cell type and its distribution (4). Other mouse models of
disorganized islet architecture, including transgenic over-
expression of hepatocyte nuclear factor (HNF)-6 (25) and
dominant-negative HNF-1 (26), also result in glucose
intolerance. In all of these models, Glut2 is absent or
largely reduced; therefore, -cell dysfunction, including
glucose sensing, is a main cause of diabetes. In Ptf1a
hypomorphic mice, however, insulin-producing cells ex-
press normal amounts of Pdx1 and Glut2, suggesting their
functional maturation. We consider the main cause of
glucose intolerance to be the inadequate number of total
-cells. From the observations during embryonic stages,
two mechanisms might be responsible: First, as a conse-
quence of reduced Ptf1a expression, substantial propor-
tion of foregut epithelial cells are misspeciﬁed to the
duodenum and CBD, resulting in the reduction of the ﬁnal
cell population that adopts a pancreatic cell-fate. Second,
reduced proliferation during early pancreatogenesis
causes inadequate expansion of endocrine precursor pools
in Ptf1a hypomorphic mutant mice. Supporting this no-
tion, preliminary analyses showed that Ngn3 expression in
pancreatic rudiments are reduced in Ptf1a hypomorphic
mutants (50  13% in Ptf1a
cre/cbll mice and 50  6% in
Ptf1a
cbll/cbll mice) compared with wild-type mice at e12.5
(n  3), although the expression level of Ngn3 per cell is
unclear. Reduced Pdx1 expression might affect Ngn3-
expressing cell formation during early pancreatigenesis in
Ptf1a hypomorphic mutants because loss of Pdx1 results
in no Ngn3-expressing cell formation in mice (27). At the
same time, islet dysmorphology itself (disturbed ratio of
each cell type and its localization) might be associated
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with -cells might disrupt the gap junctional or other
coupling that is involved in an efﬁcient insulin release (28).
Clinical implications for Ptf1a hypomorphic mutant
mice. We have already reported that hypomorphic
Ptf1a
cre/cbll and Ptf1a
cbll/cbll mice exhibit cerebellar agene-
sis similar to that of Ptf1a-null mice (14). The levels of
Ptf1a transcripts in Ptf1a
cbll/cbll embryos are dramatically
reduced in the cerebellum (26.3-fold reduction), whereas
they are more mildly affected in the hindbrain (4.5-fold
reduction) and pancreas (3.1-fold reduction) (Fig. 1 and
ref. 29). The precise mechanism that accounts for this
difference is currently unknown; however, our previous
report and current ﬁndings suggest that threshold levels to
acquire speciﬁc cell fates differ among different organs. A
nonsense mutation in Ptf1a has been recently identiﬁed as
a cause of autosomal recessively inherited permanent
neonatal diabetes associated with pancreatic and cerebel-
lar agenesis in humans (13). Although hypomoprphic
Ptf1a alleles have not been identiﬁed so far, our data
predict a possible involvement of hypomorphic Ptf1a
alleles in congenital pancreatic hypoplasia and diabetes in
humans either by mutations in the Ptf1a coding region or
deletions or single nucleotide polymorphisms in its regu-
latory sequence that are pivotal in pancreatic Ptf1a ex-
pression. In addition, our ﬁndings are also implicated in
possible islet regeneration therapy for diabetes, since
controlling gene dosage or levels/duration of gene expres-
sion might be one of the important factors for producing
pancreatic -cells in vitro.
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